DE602005019251D1 - Verwendung von acetyl l-carnitin in kombination mit propionyl l-carnitin und sildenafil zur behandlung von erektiler dysfunktion - Google Patents

Verwendung von acetyl l-carnitin in kombination mit propionyl l-carnitin und sildenafil zur behandlung von erektiler dysfunktion

Info

Publication number
DE602005019251D1
DE602005019251D1 DE602005019251T DE602005019251T DE602005019251D1 DE 602005019251 D1 DE602005019251 D1 DE 602005019251D1 DE 602005019251 T DE602005019251 T DE 602005019251T DE 602005019251 T DE602005019251 T DE 602005019251T DE 602005019251 D1 DE602005019251 D1 DE 602005019251D1
Authority
DE
Germany
Prior art keywords
carnitine
sildenafil
propionyl
acetyl
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005019251T
Other languages
German (de)
English (en)
Inventor
Aleardo Koverech
Giorgio Cavallini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of DE602005019251D1 publication Critical patent/DE602005019251D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602005019251T 2004-11-11 2005-10-19 Verwendung von acetyl l-carnitin in kombination mit propionyl l-carnitin und sildenafil zur behandlung von erektiler dysfunktion Expired - Lifetime DE602005019251D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000561A ITRM20040561A1 (it) 2004-11-11 2004-11-11 Uso della acetil l-carnitina in combinazione con propionil l-carnitina e sildenafil per il trattamento della disfunzione erettile.
PCT/EP2005/011238 WO2006050794A1 (en) 2004-11-11 2005-10-19 Use of acetyl l-carnitine in combination with propionyl l-carnitine and sildenafil for the treatment of erectile dysfunction

Publications (1)

Publication Number Publication Date
DE602005019251D1 true DE602005019251D1 (de) 2010-03-25

Family

ID=35501123

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005019251T Expired - Lifetime DE602005019251D1 (de) 2004-11-11 2005-10-19 Verwendung von acetyl l-carnitin in kombination mit propionyl l-carnitin und sildenafil zur behandlung von erektiler dysfunktion

Country Status (16)

Country Link
US (1) US8003652B2 (enExample)
EP (1) EP1811988B1 (enExample)
JP (1) JP5080263B2 (enExample)
KR (1) KR101455275B1 (enExample)
AT (1) ATE456950T1 (enExample)
CA (1) CA2585654C (enExample)
CY (1) CY1110239T1 (enExample)
DE (1) DE602005019251D1 (enExample)
DK (1) DK1811988T3 (enExample)
ES (1) ES2339265T3 (enExample)
IT (1) ITRM20040561A1 (enExample)
MX (1) MX2007005518A (enExample)
PL (1) PL1811988T3 (enExample)
PT (1) PT1811988E (enExample)
SI (1) SI1811988T1 (enExample)
WO (1) WO2006050794A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010222347A (ja) * 2009-02-24 2010-10-07 Daiichi Sankyo Healthcare Co Ltd Ｐｄｅ５阻害剤及びカルニチンを含有する医薬組成物
WO2012000634A1 (de) 2010-06-29 2012-01-05 Georg Bambach Pharmazeutische zusammensetzung zur behandlung von erektiler dysfunktion
WO2018070971A1 (ru) * 2016-10-10 2018-04-19 Товарыство З Обмэжэною Видповидальнистю Науково-Выробныча Фирма "Микрохим" Фармацевтическая композиция в форме оромукозного спрея для лечения эректильной дисфункции и легочной артериальной гипертензии

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1077260B1 (en) 1999-08-13 2010-03-31 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Parvovirus NS1 variants
IT1306722B1 (it) * 1999-10-08 2001-10-02 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di
JP2001233770A (ja) * 2000-02-23 2001-08-28 Dountsuendorufaa Udo 勃起機能不全治療用の経口薬の組合わせ
ITRM20010621A1 (it) * 2001-10-18 2003-04-18 Aldo Fassi Sali metallici non igroscopici e idrosolubili di alcanoil l-carnitine, integratori dietetici che li contengono e kit dietetici, per contrast
ITRM20010708A1 (it) * 2001-12-04 2003-06-04 Sigma Tau Ind Farmaceuti Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile.
ITRM20020620A1 (it) * 2002-12-13 2004-06-14 Sigma Tau Ind Farmaceuti Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.

Also Published As

Publication number Publication date
US8003652B2 (en) 2011-08-23
ITRM20040561A1 (it) 2005-02-11
CA2585654C (en) 2013-04-02
WO2006050794A1 (en) 2006-05-18
JP2008531466A (ja) 2008-08-14
CA2585654A1 (en) 2006-05-18
ATE456950T1 (de) 2010-02-15
PL1811988T3 (pl) 2010-07-30
PT1811988E (pt) 2010-04-08
EP1811988A1 (en) 2007-08-01
SI1811988T1 (sl) 2010-10-29
DK1811988T3 (da) 2010-05-17
EP1811988B1 (en) 2010-02-03
CY1110239T1 (el) 2015-01-14
ES2339265T3 (es) 2010-05-18
MX2007005518A (es) 2007-05-18
JP5080263B2 (ja) 2012-11-21
US20080090906A1 (en) 2008-04-17
KR101455275B1 (ko) 2014-10-27
KR20070085961A (ko) 2007-08-27

Similar Documents

Publication Publication Date Title
ATE553719T1 (de) Vorrichtung zur unterstützung eines vaginalcuffs
EA201000865A1 (ru) Комбинация ингибиторов протеинтирозинфосфатазы и гормона роста человека, предназначенная для лечения атрофии мышц и родственных нарушений
IN2004CH02386A (enExample)
ZA200608024B (en) Use of flibanserin in the treatment of premenstrual and other female sexual disorders
UA91680C2 (ru) Производные сульфаматов и сульфамидов для лечения эпилепсии и сопутствующих расстройств
ATE457729T1 (de) Verwendung von allopurinol zur behandlung von palmarer/plantarer erythrodysästhesie
DE602004015169D1 (de) Kleinkindernahrung mit proteasehemmer
DE602005019251D1 (de) Verwendung von acetyl l-carnitin in kombination mit propionyl l-carnitin und sildenafil zur behandlung von erektiler dysfunktion
CY1109051T1 (el) Χρηση καρνιτινων για την προληψη και/ή θεραπεια διαταραχων που προκαλουνται απο την ανδροπαυση
ATE380554T1 (de) Verwendung von xenon mit hypothermie zur behandlung von neugeborenen-asphyxie
ATE468849T1 (de) Idebenon zur behandlung von muskeldystrophien
AR059789A1 (es) "dominios kunitz quimericos y su uso "
BRPI0415893A (pt) métodos para tratar insÈnia em um paciente humano em necessidade do mesmo, para tratar insÈnia primária em um paciente humano adulto ou idoso em necessidade do mesmo e para melhorar o funcionamento no horário diurno em um paciente humano em necessidade do mesmo, uso do gaboxadol, e, composição farmacêutica
ATE392212T1 (de) Verwendung eines proteasom-inhibitors zur behandlung fibrotischer erkrankungen
ATE476974T1 (de) Verwendung einer kombination von l-carnitin, acetyl l-carnitin und propionyl l-carnitin zur behandlung von oligoasthenoteratospermia
DK1056358T3 (da) Anvendelse af D-tagatose som en præbiotisk næringsmiddelkomponent
MXPA05009718A (es) Uso de un fibrato y orlistato para el tratamiento de obesidad.
PH12014500597A1 (en) Pelvic immobilizer
DE602004012759D1 (de) Behandlung von fibrosen
Lee The clinical Observation on 2 cases of patients with Post-herpetic Neuralgia treated by Sa-am-acupuncture and Arctii Fructus water extrac
TNSN06147A1 (en) Use of cathepsin k inhibitors for treating of severe bone loss diseases
TW200605891A (en) Use of 7-t-butoxyiminomethylcamptothecin for the preparation of a medicament for the treatment of uterine neoplasms
BRPI0516832A (pt) uso para alfa-simpatomiméticos com uma estrutura de 2-imidazolina
CY1113707T1 (el) Χρηση ανταγωνιστων il-1 για να θεραπευεται ουρικη αρθριτιδα και ψευδοουρικη αρθριτιδα
EA200701147A1 (ru) Средство для профилактики и лечения расстройств репродуктивной системы человека "фiломек" и способ его получения

Legal Events

Date Code Title Description
8364 No opposition during term of opposition